Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

They have at least one thing in common: An exciting pipeline.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech pioneer Genentech will cut 103 jobs in its latest round of layoffs, including its head of cell therapy and 33 ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...